You are here: Industry Insights > PSA

News List

VA Study Shows Black Men Twice as Likely to Develop Prostate Cancer as Whites drugs.com
January 19, 2022
Even in a setting where white and Black people have equal access to medical care...
FDA approves Novartis’ Cosentyx to treat arthritis in children and adolescents Pharmaceutical-Business-Review
December 27, 2021
A fully human biologic, Cosentyx is developed to directly target interleukin-17A (IL-17A), a cytokine.
Serum Biomarkers Can Differentiate Psoriatic Arthritis, RA drugs.com
December 21, 2021
A serum protein biomarker panel can differentiate patients with early inflammatory arthritis with psoriatic arthritis (PsA) from those with rheumatoid arthritis (RA), according to a study recently published in Arthritis & Rheumatology.
Statin Use Does Not Change Benefits of Prostate Cancer Screening Drugs
December 09, 2021
Prostate-specific antigen (PSA) screening is associated with a lower incidence of advanced prostate cancer regardless of statin use, according to a study published online Nov. 24 in JAMA Oncology.
Tremfya® shows promise in Phase III psoriatic arthritis study EuropeanPharmaceuticalReview
November 03, 2021
Janssen has announced six new analyses of Phase III data from the DISCOVER-1 and DISCOVER-2 clinical trials, which demonstrate Tremfya® (guselkumab) inhibited radiographic progression versus placebo...
Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2506 americanpharmaceuticalreview
June 10, 2021
Bio-Thera Solutions Ltd., a commercial-stage pharmaceutical company, announced that dosing has begun in a Phase III clinical study for BAT2506, a proposed biosimilar of Simponi® (golimumab).
Tremfya® improves psoriatic arthritis joint function and skin clearance europeanpharmaceuticalreview
June 08, 2021
Over 50 percent of psoriatic arthritis patients treated with Tremfya® (guselkumab) achieved ≥20 percent improvement in joint symptoms and complete skin clearance at one year.
J&J’s Tremfya shows significant improvements for post-TNFi psoriatic arthritis patients pharmatimes
June 04, 2021
Johnson & Johnson’s (J&J) interleukin-23 (IL-23) Tremfya has demonstrated positive results in post-tumour necrosis factor (TNF) inhibitor-treated psoriatic arthritis (PsA) patients.
NICE green lights Tremfya to treat active psoriatic arthritis pharmatimes
June 01, 2021
Janssen’s IL-23 inhibitor Tremfya has been accepted for NHS use by the UK’s National Institute for Health and Care Excellence (NICE) for the treatment of active psoriatic arthritis (PsA).
Data shows long-term efficacy of Tremfya® in active psoriatic arthritis europeanpharmaceuticalreview
March 18, 2021
The joint and skin response rates of adults with active psoriatic arthritis observed with Tremfya® (guselkumab) were maintained over two years.

Previous page 1 2 3 Next page